Allison Coker, PhD

Title(s)Clinical Research Analyst, Neurology
SchoolSchool of Medicine
ORCID ORCID Icon0000-0001-5353-4653 Additional info
vCardDownload vCard
    Other Positions
    Title(s)UCSF Weill Institute for Neurosciences

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoPhDNeuroscience
    Emory UniverisityBSNeuroscience & Behavioral Biology

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder. Front Psychiatry. 2022; 13:947622. Singleton SP, Wang JB, Mithoefer M, Hanlon C, George MS, Mithoefer A, Mithoefer O, Coker AR, Yazar-Klosinski B, Emerson A, Doblin R, Kuceyeski A. PMID: 36713926; PMCID: PMC9879604.
      View in: PubMed   Mentions:
    2. Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling. Neuropharmacology. 2022 11 01; 218:109220. Henningfield JE, Coe MA, Griffiths RR, Belouin SJ, Berger A, Coker AR, Comer SD, Heal DJ, Hendricks PS, Nichols CD, Sapienza F, Vocci FJ, Zia FZ. PMID: 35987353.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    3. The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Drug Alcohol Depend. 2022 04 01; 233:109356. Nicholas CR, Wang JB, Coker A, Mitchell JM, Klaire SS, Yazar-Klosinski B, Emerson A, Brown RT, Doblin R. PMID: 35286849.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    4. Reply to: Caution at psychiatry's psychedelic frontier and Challenges with benchmarking of MDMA-assisted psychotherapy. Nat Med. 2021 10; 27(10):1691-1692. Mitchell J, Coker A, Yazar-Klosinski B. PMID: 34635856.
      View in: PubMed   Mentions: 1     Fields:    
    5. Scaling Up: Multisite Open-Label Clinical Trials of MDMA-Assisted Therapy for Severe Posttraumatic Stress Disorder. Journal of Humanistic Psychology. 2021. Wang JB, Lin J, Bedrosian L, Coker A, Jerome I, Feduccia A, Lilienstein A, Harrison C, Heimler E, Mithoefer M, Mithoefer A, Ot’alora G. M, Poulter B, Carlin S, Matthews R, Yazar-Klosinski B, Emerson A, Doblin R. View Publication.
    6. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021 06; 27(6):1025-1033. Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, Ot'alora G M, Garas W, Paleos C, Gorman I, Nicholas C, Mithoefer M, Carlin S, Poulter B, Mithoefer A, Quevedo S, Wells G, Klaire SS, van der Kolk B, Tzarfaty K, Amiaz R, Worthy R, Shannon S, Woolley JD, Marta C, Gelfand Y, Hapke E, Amar S, Wallach Y, Brown R, Hamilton S, Wang JB, Coker A, Matthews R, de Boer A, Yazar-Klosinski B, Emerson A, Doblin R. PMID: 33972795; PMCID: PMC8205851.
      View in: PubMed   Mentions: 98     Fields:    Translation:HumansCTClinical Trials
    7. The catechol-O-methyltransferase inhibitor tolcapone modulates alcohol consumption and impulsive choice in alcohol use disorder. Psychopharmacology (Berl). 2020 Oct; 237(10):3139-3148. Coker AR, Weinstein DN, Vega TA, Miller CS, Kayser AS, Mitchell JM. PMID: 32617646; PMCID: PMC7529919.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    8. Intra-VTA deltorphin, but not DPDPE, induces place preference in ethanol-drinking rats: distinct DOR-1 and DOR-2 mechanisms control ethanol consumption and reward. Alcohol Clin Exp Res. 2014 Jan; 38(1):195-203. Mitchell JM, Margolis EB, Coker AR, Allen DC, Fields HL. PMID: 24033469.
      View in: PubMed   Mentions: 15     Fields:    Translation:Animals
    9. Alcohol self-administration, anxiety, and cortisol levels predict changes in delta opioid receptor function in the ventral tegmental area. Behav Neurosci. 2012 Aug; 126(4):515-22. Mitchell JM, Margolis EB, Coker AR, Fields HL. PMID: 22708955; PMCID: PMC3669671.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    10. The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers. J Clin Psychopharmacol. 2012 Apr; 32(2):269-72. Mitchell JM, Grossman LE, Coker AR, Messing RO. PMID: 22367657.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    11. Reliability in the identification of midbrain dopamine neurons. PLoS One. 2010 Dec 09; 5(12):e15222. Margolis EB, Coker AR, Driscoll JR, Lemaître AI, Fields HL. PMID: 21151605; PMCID: PMC3000317.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansAnimalsCells